Working… Menu

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients (Nivo-TIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03374839
Recruitment Status : Recruiting
First Posted : December 15, 2017
Last Update Posted : September 6, 2019
Bristol-Myers Squibb
Information provided by (Responsible Party):
Nantes University Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 12, 2023
Estimated Study Completion Date : March 12, 2023